Positive interim results from the Phase III DESTINY-Breast09 trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), ...

In recent years, the treatment landscape of HR+/HER2−ve breast cancer has completely changed with the introduction of particularly active targeted drugs, from CDK4/6 inhibitors, mTOR inhibitors, and ...

In a Phase I study presented at AACR's annual meeting, 71 percent of patients who hadn't received a prior anti-HER2 ADC responded to the drug.

A new commercial for AstraZeneca’s Truqap constructs a vision of the extra time that the AKT inhibitor can unlock for some ...

Phase 1b Beamion LUNG-1 trial data at AACR 2025 showed zongertinib yielded responses in pretreated HER2-mutant NSCLC, ...

Runimotamab plus trastuzumab resulted in positive clinical activity and tolerability over runimotamab alone in patients with ...

A combination of pertuzimab and Enhertu can slow disease progression and improve survival in people with HER2-positive ...

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with ...

Soriot discussed the impact of potential tariffs during a call on AstraZeneca's earnings. For the three months ended March 31, during which period the firm netted $13.59 billion in total revenue, an ...

The investigational oral tyrosine kinase inhibitor (TKI) zongertinib showed promise in patients with previously treated HER2 ...

Boehringer Ingelheim’s drug candidate for human epidermal growth factor receptor 2 (HER2)-mutated non-small cell lung cancer ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...